Article

GD2 targeting CAR T cells for neuroblastoma

2024-07-11

Abstract excerpt

Treatment of neuroblastoma is a significant clinical unmet need in paediatric oncology epitomised by high-risk disease in which relapse is common and outcomes for children with relapse or primary refractory disease are typically poor, with 4-year progression-free survival for relapse/refractory disease of 6 %. Immunotherapy targeting disialoganglioside GD2 using monoclonal antibodies (mAb) has become a component o...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 473ecc7d-5fb7-559c-882a-62110d55fc09
DOI: 10.1016/j.ejcped.2024.100179

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

GD2 targeting CAR T cells for neuroblastomaDOI 10.1016/j.ejcped.2024.100179Read

An Optimized GD2-Targeting Retroviral Cassette for More Potent and Safer Cellular Therapy of Neuroblastoma and Other CancersSemantic proximity Read

Immunotherapy of Neuroblastoma: Facts and HopesSemantic proximity Read

GD2-specific Chimeric Antigen Receptor-modified T Cells for the treatment of Refractory and/or Recurrent Neuroblastoma in Pediatric PatientsSemantic proximity Read

Current Knowledge and Perspectives of Immunotherapies for NeuroblastomaSemantic proximity Read

State of the Art in Immunotherapy of NeuroblastomaSemantic proximity Read

Biological Insight and Recent Advancement in the Treatment of NeuroblastomaSemantic proximity Read

Eighteen-year survival after GD2-directed Chimeric Antigen Receptor-Modified Immune Effector Cell Treatment for NeuroblastomaSemantic proximity Read

Anti-GD2 antibody therapy alters the neuroblastoma tumor microenvironment and extends survival in <i>TH-MYCN</i> miceSemantic proximity Read

Carbohydrate Targets for CAR T Cells in Solid Childhood CancersSemantic proximity Read

CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with NeuroblastomaSemantic proximity Read

Novel Therapies for Relapsed and Refractory NeuroblastomaSemantic proximity Read

Inhibition of MEK pathway enhances the antitumor efficacy of chimeric antigen receptor T cells against neuroblastoma.Semantic proximity Read